Yes, Xgeva (denosumab) is a monoclonal antibody. It works by inhibiting RANKL (receptor activator of nuclear factor kappa-Β ligand), which is involved in the formation, function, and survival of osteoclasts, the cells responsible for bone resorption. Xgeva is primarily used to prevent skeletal-related events in patients with bone metastases from solid tumors.
Monoclonal antibody
An agonisitic monoclonal antibody is an immunological term for a monoclonal antibody which attempts to boost the immune system in order to fight infection or cancer.
A monoclonal antibody is a highly specific antibody that has been formed in a laboratory setting. It is made up of clones from a hybrid cell made from a fusion of B-cells with a tumor cell.
Humira (generic name adalimumab) Is The First Human Monoclonal Antibody Approved For Rheumatoid Arthritis.
Monoclonal antibody therapy is administered through injections. How often it should be perfomed varies depending on what your doctor recommends.
Monoclonal antibody production can be seen as very valuable as it creates an insight into diagnosing in vitro anomalies. Monoclonal antibodies are derived from cloned cells and allow people to study in depth anomalies that occur in humans and in reproduction.
by the help of hybridoma technology. single type of B cell which is sensitized with single epitope of antigen fysed with a myeloma cell. then that fused cell produce single type of antibody....that is monoclonal antibody.....
MoAb stands for "monoclonal antibody"
Oh, dude, denosumab is used to treat osteoporosis in postmenopausal women and men at high risk of fractures. It works by blocking a protein that promotes bone breakdown. So, like, it helps keep those bones strong and less likely to break.
Polyclonal antibody recognizes several epitopes on the target protein while monoclonal antibody recognizes only single epitope. Sometimes, monoclonal antibodies are not able to precipitate the antigen because the epitope might need to be exposed on the surface of the antigen to be recognized by the antibody. Since the epitope might be hidden and it's a single epitope that is recognized by the monoclonal antibody, the propability of the antibody to reconize the epitope is lower compared with the polyclonal antibody that recognizes several epitopes on the target protein.
Xolair is marketed as omalizumab. It is a monoclonal antibody used to treat allergic conditions such as asthma and chronic idiopathic urticaria by targeting and neutralizing immunoglobulin E (IgE).
Polyclonal antibody recognizes several epitopes on the target protein while monoclonal antibody recognizes only single epitope, hence monoclonal antibodies are more specific than polyclonal antibodies. However, sometimes MAbs are not able to precipitate the antigen because the epitope might need to be exposed on the surface of the antigen to be recognized by the antibody. Since some of the epitope might be hidden and it's a single epitope that is recognized by the monoclonal antibody, the propability of the antibody to reconize the epitope is lower compared with the polyclonal antibody that recognizes several epitopes on the target protein this is the reason for the tendency of polyclonal antibodies to have cross-reaction as compared to MAbs. by Victor S Gruezo Jr